{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/deep-vein-thrombosis/prescribing-information/parenteral-anticoagulants/","result":{"pageContext":{"chapter":{"id":"15bc2153-6b1c-5a58-9c8d-25d9978f2dde","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants","depth":2,"htmlHeader":"<!-- begin field ecaab143-d48c-4896-b788-cc955f9de414 --><h2>Parenteral anticoagulants</h2><!-- end field ecaab143-d48c-4896-b788-cc955f9de414 -->","summary":"","htmlStringContent":"<!-- begin item a80a274d-0ebc-4bb4-b134-77cdded69c8a --><!-- begin field 634a9039-97d2-4957-90be-7193469ec379 --><ul><li>The parenteral anticoagulants licensed for the treatment of deep vein thrombosis are [<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">Joint Formulary Committee, 2019</a>]: <ul><li>Low molecular weight heparins (dalteparin, enoxaparin, and tinzaparin).</li><li>Fondaparinux, a synthetic pentasaccharide that inhibits activated factor X.</li></ul></li><li>See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/prescribing-information/parenteral-anticoagulants/#dalteparin\">Prescribing issues - dalteparin</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/prescribing-information/parenteral-anticoagulants/#enoxaparin\">Prescribing issues - enoxaparin</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/prescribing-information/parenteral-anticoagulants/#tinzaparin\">Prescribing issues - tinzaparin</a>, or <a class=\"topic-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/prescribing-information/parenteral-anticoagulants/#fondaparinux\">Prescribing issues - fondaparinux</a> for more information on prescribing a 24-hour dose of these anticoagulants.</li></ul><!-- end field 634a9039-97d2-4957-90be-7193469ec379 --><!-- end item a80a274d-0ebc-4bb4-b134-77cdded69c8a -->","topic":{"id":"c1b45e75-436b-56a1-a385-f8422d715e82","topicId":"a4df6bb3-1690-4ec4-9cba-0dcff60cc7ef","topicName":"Deep vein thrombosis","slug":"deep-vein-thrombosis","lastRevised":"Last revised in November 2020","chapters":[{"id":"043e731c-3abf-53ee-a31d-8d884bd3bc70","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bf477005-0407-58ad-9621-2529440a1912","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0d6b5798-088f-5468-84b7-a93cfe9e70d4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c5e88810-6d89-56ef-9120-966cbdac34da","slug":"changes","fullItemName":"Changes"},{"id":"06d2c305-090e-5332-b7a1-b6be267bcd41","slug":"update","fullItemName":"Update"}]},{"id":"0e61afec-aecd-50f3-8f6d-ef8da1dc9003","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"acd9fd74-ef09-56e2-b4e4-65e22ddc6269","slug":"goals","fullItemName":"Goals"},{"id":"13b37b76-163e-58e7-9ed4-add17978eb23","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c283b01d-3860-51e0-bb61-d68a12c34e68","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6c0366d1-9980-5dc1-8946-44e5030bc691","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"707aca3b-1b4f-52aa-848d-6d44d4337f41","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9b9c8c09-f068-59bc-ad89-ca508289d1b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"341b7f8d-b4d0-58b0-8198-4c563cb9f40e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b31fd103-9bbb-5216-ad96-7ce04f610584","slug":"definition","fullItemName":"Definition"},{"id":"f95afcb9-845a-579a-a5bd-b95f7163d1b9","slug":"incidence","fullItemName":"Incidence"},{"id":"fb6ff0cb-ba3b-5075-9e5e-52380bc0ecd3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b828ffa2-5a2d-5a7d-89c2-3b5ce4c27b07","slug":"complications","fullItemName":"Complications"}]},{"id":"837dc43f-aac0-51fa-af65-afb4b7a54467","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"699e0a9f-a13f-535b-91e2-967968d57b5e","slug":"when-to-suspect-dvt","fullItemName":"When to suspect DVT"},{"id":"e436c043-ce99-5fc5-b99e-deb107b997e9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9caf86d2-a390-5cb8-bcec-dd055468ba41","fullItemName":"Management","slug":"management","subChapters":[{"id":"edd98243-d8d1-5402-a55c-9d8de8e68068","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"02795cd7-4068-5ef2-840c-914a96cfd71b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"15bc2153-6b1c-5a58-9c8d-25d9978f2dde","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants"},{"id":"7e7201d1-4e56-53ec-95ac-c64ea70060e4","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants"}]},{"id":"a5e9e695-9150-5486-8075-1fa6c8b75fba","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06671f87-530c-52a1-800c-749cdb70cad7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"63cf38fe-dc13-5253-93e7-bb3da5b958a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"439fde91-9bb2-561f-8d66-de440bc5e387","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0f076b49-f0f3-597a-ba30-f5f3f414beae","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5e81047f-a3c4-52f4-ad24-f951952ea809","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"17391681-76bf-5417-9a9c-6e66245c631d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2cd34860-5410-5109-8de9-0227c8af1e62","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"02795cd7-4068-5ef2-840c-914a96cfd71b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b8ae4839-9b7f-5648-b736-7d0e0407d15e","slug":"dalteparin","fullItemName":"Dalteparin","depth":3,"htmlHeader":"<!-- begin field a47d5fd5-6855-4525-895c-0c95aebe5b88 --><h3>What should I be aware of when prescribing dalteparin?</h3><!-- end field a47d5fd5-6855-4525-895c-0c95aebe5b88 -->","summary":"","htmlStringContent":"<!-- begin item 7c55e952-bfb7-44b0-9ddf-91e3823020c0 --><!-- begin field a816a6d2-10f0-4cb4-b3e4-f238b2132f2b --><ul><li>Dalteparin should be administered subcutaneously.</li><li>The recommended dose of dalteparin for the treatment of deep vein thrombosis is:<ul><li><strong>For the single-dose injections </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">Joint Formulary Committee, 2019</a>]</strong>: <ul><li>Body weight less than 46 kg — 7500 units once daily.</li><li>Body weight 46–56 kg — 10,000 units once daily.</li><li>Body weight 57–68 kg — 12,500 units once daily.</li><li>Body weight 69–82 kg — 15,000 units once daily.</li><li>Body weight 83 kg and over — 18,000 units once daily.</li></ul></li></ul></li><li><strong>Dalteparin is contraindicated in people </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2016</a>]</strong><strong>: </strong><ul><li>With current (or history of) heparin-induced thrombocytopenia.</li><li>With acute gastroduodenal ulcer; cerebral haemorrhage; known haemorrhagic diathesis (a condition causing a predisposition to bleed) or other active haemorrhage; serious coagulation disorders; acute or subacute septic endocarditis; haemorrhagic pericardial effusion and haemorrhagic pleural effusion; and injuries to and operations on the central nervous system, eyes, and ears.</li><li>Who have suffered a recent (within 3 months) stroke, unless due to systemic emboli.</li><li>Note: the needle shield may contain latex (natural rubber) that may cause severe allergic reactions in individuals with hypersensitivity to latex (natural rubber) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2020a</a>].</li></ul></li><li>More detailed information on prescribing dalteparin is available in the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"f3216255-36bc-49b4-943b-a993009a5f74\">BNF</a>) and the relevant Summary of Product Characteristics listed in the electronic Medicines Compendium (eMC) (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"41ee3ff4-9c5c-43bc-a17c-a993009a5f9e\">www.medicines.org.uk</a>) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI Medicines Compendium, 2013a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI Medicines Compendium, 2013b</a>]<strong>.</strong></li></ul><!-- end field a816a6d2-10f0-4cb4-b3e4-f238b2132f2b --><!-- end item 7c55e952-bfb7-44b0-9ddf-91e3823020c0 -->","subChapters":[]},{"id":"39c690d2-69c5-5330-bbf6-c2ee62ea9eb4","slug":"enoxaparin","fullItemName":"Enoxaparin","depth":3,"htmlHeader":"<!-- begin field 49fc5aa5-d193-4ed8-8fa3-4c6e6e4bb525 --><h3>What should I be aware of when prescribing enoxaparin?</h3><!-- end field 49fc5aa5-d193-4ed8-8fa3-4c6e6e4bb525 -->","summary":"","htmlStringContent":"<!-- begin item 66225bbf-bd4f-49b9-8ecd-55fb17b0c0a9 --><!-- begin field 805b5feb-f513-458d-8de2-678339f0327f --><ul><li>Enoxaparin should be administered subcutaneously.</li><li>The recommended dose of enoxaparin for the treatment of deep vein thrombosis is 1.5 mg per kg (150 units per kg) once daily [<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">Joint Formulary Committee, 2019</a>]. </li><li><strong>Enoxaparin is contraindicated in people with </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2019c</a>]</strong><strong>:</strong> <ul><li>Current (or history of) heparin-induced thrombocytopenia.</li><li>Acute bacterial endocarditis.</li><li>Active major bleeding, major trauma, and conditions with a high risk of uncontrolled bleeding, including recent haemorrhagic stroke, recent brain, spinal or ophthalmic surgery, or gastrointestinal ulcer. </li></ul></li><li>More detailed information on prescribing enoxaparin is available in the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"33926a7c-1745-41f4-881c-a98e002492a9\">BNF</a>) and the relevant Summary of Product Characteristics listed in the electronic Medicines Compendium (eMC) (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"1d50e5a7-fabc-4fab-9985-a98e002492c1\">www.medicines.org.uk</a>) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2019c</a>]. </li></ul><!-- end field 805b5feb-f513-458d-8de2-678339f0327f --><!-- end item 66225bbf-bd4f-49b9-8ecd-55fb17b0c0a9 -->","subChapters":[]},{"id":"3e44098a-c034-5fa4-9311-5ecdaf8a10ce","slug":"tinzaparin","fullItemName":"Tinzaparin","depth":3,"htmlHeader":"<!-- begin field fed8278b-cd59-49a3-ab6e-a83d1ab5fa91 --><h3>What should I be aware of when prescribing tinzaparin?</h3><!-- end field fed8278b-cd59-49a3-ab6e-a83d1ab5fa91 -->","summary":"","htmlStringContent":"<!-- begin item 244452ec-4e90-4fb0-99e0-f98e6f609d42 --><!-- begin field 65a986bf-5847-4b6d-b1e9-d845928ba8cb --><ul><li>Tinzaparin should be administered subcutaneously.</li><li>The recommended dose of tinzaparin for the treatment of deep vein thrombosis is 175 units per kg once daily [<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">Joint Formulary Committee, 2019</a>]. </li><li><strong>Tinzaparin is contraindicated in people with </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2018a</a>]</strong><strong>:</strong> <ul><li>Acute bacterial endocarditis.</li><li>Current (or history) of heparin-induced thrombocytopenia.</li><li>Active major bleeding, major trauma, and conditions with a high risk of uncontrolled bleeding, including recent haemorrhagic stroke, recent spinal or ophthalmic surgery, or gastrointestinal ulcer. </li></ul></li><li>More detailed information on prescribing tinzaparin is available in the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"eda502b3-3b9d-481a-a74e-a993003a3fac\">BNF</a>) and the relevant Summary of Product Characteristics listed in the electronic Medicines Compendium (eMC) (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"166983a3-c2af-4d00-85aa-a993003a3fd7\">www.medicines.org.uk</a>) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2018a</a>]. </li></ul><!-- end field 65a986bf-5847-4b6d-b1e9-d845928ba8cb --><!-- end item 244452ec-4e90-4fb0-99e0-f98e6f609d42 -->","subChapters":[]},{"id":"6ff9ecaa-34fd-520e-8d40-f0f76bb1083f","slug":"fondaparinux","fullItemName":"Fondaparinux","depth":3,"htmlHeader":"<!-- begin field e9f29c49-33b0-4a3d-a707-34889ad7bd5d --><h3>What issues should I be aware of when prescribing fondaparinux?</h3><!-- end field e9f29c49-33b0-4a3d-a707-34889ad7bd5d -->","summary":"","htmlStringContent":"<!-- begin item b6eaf4c3-51b9-4115-97ea-ca11ce9bfc26 --><!-- begin field 2f5d3242-7013-45a5-a663-0cc79271eb18 --><ul><li>Fondaparinux should be administered subcutaneously.</li><li><strong>The recommended dose of fondaparinux for the treatment of deep vein thrombosis is </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2019d</a>]</strong> <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">Joint Formulary Committee, 2019</a>]</strong><strong>: </strong><ul><li>Body weight less than 50 kg — 5 mg every 24 hours.</li><li>Body weight 50–100 kg — 7.5 mg every 24 hours.</li><li>Body weight over 100 kg — 10 mg every 24 hours.</li></ul></li><li><strong>Fondaparinux is contraindicated in people with </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2019d</a>]</strong><strong>:</strong> <ul><li>Active clinically significant bleeding.</li><li>Acute bacterial endocarditis.</li><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 30 mL per minute per 1.73m<sup>2</sup>).</li></ul></li><li>More detailed information on prescribing fondaparinux is available in the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"3cdf8e62-3789-4990-b358-a98c00f55ab9\">BNF</a>) and the relevant Summary of Product Characteristics listed in the electronic Medicines Compendium (eMC) (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"783ff551-a5fe-4df1-a49e-a98c00f55ae3\">www.medicines.org.uk</a>) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">ABPI, 2019d</a>]. </li></ul><!-- end field 2f5d3242-7013-45a5-a663-0cc79271eb18 --><!-- end item b6eaf4c3-51b9-4115-97ea-ca11ce9bfc26 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}